Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 441Magnetic Resonance Spectroscopy 340pembrolizumab 286Biopsy 242Carboplatin 228Cisplatin 193Cyclophosphamide 177Paclitaxel 160Nivolumab 152Gemcitabine 147Bevacizumab 123Radiotherapy 120Dexamethasone 110Pemetrexed 101fludarabine 95Fluorouracil 95atezolizumab 90Radiation 90venetoclax 89Docetaxel 88Doxorubicin 86Oxaliplatin 85durvalumab 84Rituximab 83Leucovorin 81Capecitabine 75Prednisone 72Lenalidomide 69X-Rays 67Etoposide 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Paroxetine × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡